The EPS beat and clear FDA regulatory path for CAD-1005 are positive catalysts. However, the company needs additional capital to fund the Phase 3 trial. Monitor for financing announcements and initiation of patient enrollment in the pivotal study.
Price Chart
Executive Summary
Cadrenal Therapeutics reported Q1 2026 EPS of -$1.04, beating the -$1.57 consensus by 33.8%. The company also announced receipt of official FDA End-of-Phase 2 meeting minutes providing a clear path to a pivotal Phase 3 trial for CAD-1005 in HIT, with an NDA submission projected in 2029. Subsequent to quarter end, the company completed a $2.5 million financing to support near-term development activities.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$1.04 vs consensus -$1.57 (beat by 33.8%)
- Received official FDA EOP2 meeting minutes guiding Phase 3 registration trial for CAD-1005 in HIT
- Plan to advance directly to randomized, blinded, placebo-controlled Phase 3 study in ~120 patients
- Phase 2 data showed >25% absolute reduction in thrombotic events with CAD-1005
- Cash and cash equivalents of $2.3M as of March 31, 2026, with subsequent $2.5M financing on April 1
- Net loss of $2.5M in Q1 2026 vs $3.8M in Q1 2025
Financial Impact
EPS surprise of +33.8% vs consensus; $2.5M net loss; cash position $2.3M
Risk Factors
- Requires significant additional capital to complete Phase 3 trial; current cash may be insufficient
- Phase 3 trial may fail to meet endpoints
- Competing therapies or changes in standard of care for HIT
- Risk of dilution from future equity offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290023 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | 8-K | $0.9723 | awaiting T+60 | — | $0.9100 (−6.41%) |
Aug 31, 2026 8w ago | 8-K | $1.75 | awaiting T+60 | — | $0.9100 (−48.00%) |
Jul 21, 2026 13w ago | 8-K | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9100 (−58.06%) |
Jul 21, 2026 13w ago | EFFECT | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9100 (−58.06%) |
Jul 1, 2026 16w ago | Press Release | $3.60 $1.12 | ▲ +68.89% | ▲ +71.94% | $0.9100 (+74.72%) |
Jun 29, 2026 16w ago | 8-K | $3.34 $1.32 | ▼ −60.48% | ▼ −64.04% | $0.9100 (−72.75%) |
Jun 18, 2026 18w ago | 8-K | $3.50 $1.06 | ▼ −69.71% | ▼ −71.61% | $0.9100 (−74.00%) |
Jun 15, 2026 18w ago | 144 | $3.04 $1.18 | ▲ +61.18% | ▲ +62.18% | $0.9100 (+70.07%) |
May 7, 2026 24w ago | Press Release | $6.02 $1.96 | ▼ −67.44% | ▼ −71.27% | $0.9100 (−84.88%) |
Apr 30, 2026 25w ago | 8-K | $6.67 $2.06 | ▼ −69.12% | ▼ −72.22% | $0.9100 (−86.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers